



***Weight-based Dosing Strategies  
for Factor Replacement Therapy in  
Hemophilia A and B***

---

**Participant Request**

**March 2016**

**Center for Evidence-based Policy  
Medicaid Evidence-based Decisions Project (MED)**

Oregon Health & Science University  
3030 SW Moody, Suite 250  
Mailstop MDYCEBP  
Portland, OR 97201  
Phone: 503.494.2182  
Fax: 503.494.3807

[www.ohsu.edu/policycenter](http://www.ohsu.edu/policycenter)

## Table of Contents

Objectives.....	1
Background .....	1
Table 1. <i>Description of Factor Replacement Therapy Protocols</i> .....	2
PICO and Key Questions.....	2
Methods .....	2
Findings .....	2
Conclusions and Limitations .....	5
Appendix A: <i>Search Strategy</i> .....	6
References .....	7

## Objective

To summarize the evidence on comparative effectiveness and costs of factor replacement dosing strategies based on ideal body weight (IDW), rather than actual body weight (ABW).

## Background

Hemophilia is an inherited clotting disorder characterized by recurrent bleeding episodes. The most common types of hemophilia are hemophilia A, also known as factor VIII deficiency, and hemophilia B, or factor IX deficiency. Both are X-linked inherited disorders that manifest in male children of carrier females. Hemophilia A is the more common type, occurring in about 1 in 5,000 live male births, compared to hemophilia B, which occurs in about 1 in 30,000 live male births (Hoots & Shapiro, 2016). Hemophilia is classified as mild, moderate, or severe based on factor activity level. Those with severe hemophilia are more likely to have spontaneous bleeding and be younger when they experience their first bleeding episode. Hemophilia A is more likely to be severe than is hemophilia B (Hoots & Shapiro, 2016).

Hemophilia is an inherited clotting disorder characterized by recurrent bleeding episodes. The most common types of hemophilia are hemophilia A, also known as factor VIII deficiency, and hemophilia B, or factor IX deficiency. Both are X-linked inherited disorders that manifest in male children of carrier females. Hemophilia A is the more common type, occurring in about 1 in 5,000 live male births, compared to hemophilia B, which occurs in about 1 in 30,000 live male births (Hoots & Shapiro, 2016). Hemophilia is classified as mild, moderate, or severe based on factor activity level. Those with severe hemophilia are more likely to have spontaneous bleeding and be younger when they experience their first bleeding episode. Hemophilia A is more likely to be severe than is hemophilia B (Hoots & Shapiro, 2016).

### *Factor Replacement Therapy*

Factor VIII and IX products are used to treat hemophilia A and B, respectively. Factor products are derived from human plasma or produced from cell lines (recombinant products). Factor replacement is used to treat acute bleeding episodes, or as prophylaxis to prevent bleeding. Prophylactic factor replacement therapy is further classified as primary, secondary, tertiary, or intermittent (periodic) (Table 1) (Srivastava et al., 2013). The goal of prophylaxis is to prevent bleeding and to preserve normal musculoskeletal function.

**Table 1. Description of Factor Replacement Therapy Protocols**

<b>Protocol</b>	<b>When Initiated</b>
Episodic treatment	At the time of clinically evident bleeding; to treat pain and serious bleeding
Primary prophylaxis	Before second joint bleed, in the absence of documented joint disease
Secondary prophylaxis	After second joint bleed and before onset of joint disease
Tertiary prophylaxis	After onset of joint disease
Intermittent prophylaxis	Given to prevent bleeding for periods not exceeding 45 weeks in a year

Source: Adapted from Srivastava et al., 2013

Dosing of factor replacement is based on the patient's weight. For example, the dose of Factor VIII is calculated by multiplying the patient's weight in kilograms by the factor level in IU/dl desired, multiplied by 0.5. The factor IX dose is calculated by multiplying the patient's weight in kilograms by the factor level desired. The factor level desired varies based on duration of treatment and type of hemorrhage (Srivastava et al., 2013). The effectiveness of factor replacement therapy is assessed by measuring factor levels, with the target plasma level based on observations of better outcomes in patients with mild hemophilia.

Because factor dosing is based on patient weight, overweight and obese patients receive a higher dose compared to patients of similar height who are not overweight. However, since fatty tissues contains less blood volume than muscle of the same weight, dosing factor based on the patient's weight overestimates total blood volume (Wong et al., 2011). If dosing is based on IDW, rather than ABW, this could reduce the amount of factor used without increasing risk of bleeding or other adverse events.

A 2005 survey found that 34.5% of adults with hemophilia ages 20 and older in the United States were overweight and 23.5% were obese (Wong et al., 2011). The same survey found that 16.4% of children with hemophilia were overweight, compared to 13.7% in the general population. A more recent study from the Netherlands found an increase in obesity that paralleled that of the general population. Inactivity may contribute to obesity in patients with hemophilia, and hemophilia care guidelines stress the importance of promoting safe exercise and good nutrition (Srivastava et al., 2013). In addition to higher factor usage, obesity puts more pressure on joints and can contribute to bleeding into joints and arthropathy (Wong et al., 2011).

## **PICO and Key Questions**

### *Populations*

- Adults or children with hemophilia A or B receiving factor replacement treatment

### *Interventions*

- Factor dosing based on IBW

### *Comparator*

- Factor dosing based on ABW

### *Outcomes*

- Pharmacokinetic measurements
- Total factor use
- Long-term joint outcomes (arthropathy)
- Cardiovascular events
- Cost-effectiveness

### *Key Questions*

1. What is the comparative effectiveness and cost-effectiveness of factor dosing based on IBW versus ABW?
2. Does the comparative effectiveness of factor dosing based on IBW vary by:
  - a. Patient characteristics (age, ethnicity, hemophilia type, presence of inhibitors)
  - b. Prophylactic use vs on-demand use
  - c. Type of factor replacement

## **Methods**

To identify evidence and clinical practice guidelines, Center for Evidence-based Policy (Center) staff searched Medicaid Evidence-based Decision Project core sources and Ovid MEDLINE® using terms for factor replacement and dosing (Appendix A). Center staff also searched reference lists of included review articles and Google Scholar for articles citing included and/or relevant studies.

## **Findings**

### *Clinical Practice Guidelines*

Center staff identified hemophilia treatment guidelines from the United States, United Kingdom, Italy, and Australia (Australian Haemophilia Centre Directors' Organisation, 2016; Collins et al., 2013; National Hemophilia Foundation, 2015; Rocino et al., 2014). With one exception, these guidelines recommend using the patient's ABW to calculate factor

replacement dose and do not address different factor dosing strategies based on ABW versus IBW.

Australian guidelines, still in draft form, differ from the World Federation of Hemophilia guidelines and others in that they recommend factor dosing of obese patients based on IBW (Australian Haemophilia Centre Directors' Organisation, 2016). The final guidelines are expected to be released by June 30, 2016. The citation for this recommendation is an observational study of only six patients, discussed below (Graham & Jaworski, 2014).

### *Evidence*

Searches did not identify systematic reviews or randomized controlled trials (RCTs) comparing dosing strategies based on actual versus ideal body weight. Center staff identified only uncontrolled observational studies addressing the key questions.

A study of six obese patients with hemophilia A (5 of whom had severe disease) used IBW rather than ABW to calculate dose of their usual factor VIII replacement prophylaxis (Graham & Jaworski, 2014). This regimen resulted in a mean 48.9% reduction in factor product usage over 3 months compared to ABW-based dosing. This translated to an annual mean savings of \$133,000 per patient, based on average wholesale price. The regimen was not associated with an increase in bleeding frequency or other adverse events during the study period. Despite the positive results, caution should be taken with the findings of this study. There were only six patients in the sample, which limits both the results and generalizability of the study. Additionally, no control group was used, which may significantly bias the findings by inflating the results in a positive direction. Further research should be done to replicate these findings in a larger sample with a more rigorous study design.

Three pharmacokinetic studies by the same author have found that dosing based on BMI resulted in higher factor VIII recovery levels in overweight patients (Henrard & Hermans, 2015; Henrard, Speybroeck, & Hermans, 2011, 2013). An analysis of data from eight pharmaceutical industry-sponsored RCTs examined the effect of being overweight or underweight on factor VIII recovery in 201 adults with hemophilia A (Henrard et al., 2013). Less than 5% of patients were underweight, 25.9% were overweight, and 17.4% were obese. In a regression analysis, BMI was the strongest predictor of Factor VIII recovery (citation). The researchers concluded that the assumed standard rise of 2%/IU in factor VIII /kg infused dose does not apply to those with a BMI in either underweight or obese BMI categories, and recommended that IBW be used to calculate dosing in underweight and overweight patients. Median factor recovery was 1.60, 2.14, and 2.70 IU<sup>-1</sup> dL<sup>-1</sup> IU kg<sup>-1</sup>, respectively, for those with BMI below 20.3, 20.3 to 29.5, and 29.6 or more. A more recent study (Henrard & Hermans, 2015) used the same methods to examine the impact of being overweight on factor VIII dosing among 66 children with hemophilia A, and found a similar relationship between BMI and factor VIII recovery.

A recent pharmacoeconomic analysis used chart review data from the entire hemophilia population living in Mississippi to identify children ages 2 to 18 years on factor prophylaxis who exceeded their IBW (n = 20) (Majumdar et al., 2011). The analysis concluded that an IBW dosing strategy would result in a projected monthly cost savings of over \$120,000 if 20 overweight/obese pediatric patients were dosed at their IBW. This translated to nearly \$1.5 million per year. The study's authors did not address whether an ABW-based dosing strategy should be used in overweight/obese patients, but rather highlighted the importance of obesity prevention in patients with hemophilia.

### *Trial in Progress*

A Phase 2 [RCT](#) to assess whether IBW is more accurate than ABW in calculating factor VIII dosing in adults is in progress, with an estimated completion date of August 2017.

### **Conclusions and Limitations**

Center staff did not identify any RCTs or systematic reviews on the comparative effectiveness of dosing factor replacement based on ABW or IBW. One very small observational study concluded that a strategy based on IBW would result in a reduction in prophylactic factor usage of almost 50% over 3 months, and generate significant cost savings. The long-term effect of this strategy has not been evaluated, however. A trial in progress will evaluate this question. Obesity prevention and treatment efforts aimed at patients with hemophilia may lead to reduced factor usage even if an IBW strategy were not implemented, and may also lead to better general health outcomes and quality of life for patients.

## **Appendix A: Search Strategy**

Database: Ovid MEDLINE(R) without Revisions <1996 to February Week 4 2016>

- 1 exp Factor VIII/ or factor replacement.mp.
- 2 weight-based dosing.mp.
- 3 1 and 2
- 4 Factor VIII/ad [Administration & Dosage]
- 5 Factor IX/ad [Administration & Dosage]
- 6 4 or 5
- 7 limit 6 to (english language and humans)
- 8 limit 7 to (meta analysis or systematic reviews)



## References

- Australian Haemophilia Centre Directors' Organisation. (2016). *Guidelines for the management of haemophilia in Australia (public consultation draft)*. Retrieved from <http://www.blood.gov.au/system/files/documents/public-consultation-draft-haemophilia-guidelines-11-nov-2015.pdf>
- Collins, P. W., Chalmers, E., Hart, D. P., Liesner, R., Rangarajan, S., Talks, K., ... Doctors, U. K. H. C. (2013). Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. *British Journal of Haematology*, 160(2), 153-170. DOI: <http://dx.doi.org/10.1111/bjh.12091>
- Graham, A., & Jaworski, K. (2014). Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. *Haemophilia*, 20(2), 226-229. DOI: <http://dx.doi.org/10.1111/hae.12300>
- Henrard, S., & Hermans, C. (2015). Impact of being overweight on factor VIII dosing in children with haemophilia A. *Haemophilia*, 1-7.
- Henrard, S., Speybroeck, N., & Hermans, C. (2011). Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.[Erratum appears in J Thromb Haemost. 2012 Jan;10(1):165]. *Journal of Thrombosis & Haemostasis*, 9(9), 1784-1790. DOI: <http://dx.doi.org/10.1111/j.1538-7836.2011.04431.x>
- Henrard, S., Speybroeck, N., & Hermans, C. (2013). Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. *Haematologica*, 98(9), 1481-1486. DOI: <http://dx.doi.org/10.3324/haematol.2013.084038>
- Hoots, W. K., & Shapiro, A. D. (2016). Clinical manifestations and diagnosis of hemophilia. *UpToDate*. Retrieved from <http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hemophilia>
- Majumdar, S., Ostrenga, A., Latzman, R. D., Payne, C., Hunt, Q., Morris, A., & Iyer, R. (2011). Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution. *Haemophilia*, 17(4), 717-718. DOI: <http://dx.doi.org/10.1111/j.1365-2516.2010.02462.x>
- National Hemophilia Foundation. (2015). Medical and Scientific Advisory Council (MASAC) recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (revised August 2015). New York.
- Rocino, A., Coppola, A., Franchini, M., Castaman, G., Santoro, C., Zanon, E., ... Italian Association of Haemophilia Centres Working, P. (2014). Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.[Erratum appears in Blood Transfusion 2015 Jan;13(1):167; PMID: 25633878]. *Blood Transfusion*, 12(4), 575-598. DOI: <http://dx.doi.org/10.2450/2014.0223-14>

- Srivastava, A., Brewer, A. K., Mauser-Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., ... Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. (2013). Guidelines for the management of hemophilia. *Haemophilia*, 19(1), e1-47. DOI: <http://dx.doi.org/10.1111/j.1365-2516.2012.02909.x>
- Wong, T. E., Majumdar, S., Adams, E., Bergman, S., Damiano, M. L., Deutsche, J., ... Healthy Weight Working, G. (2011). Overweight and obesity in hemophilia: a systematic review of the literature. *American Journal of Preventive Medicine*, 41(6 Suppl 4), S369-375. DOI: <http://dx.doi.org/10.1016/j.amepre.2011.09.008>

## About the Center for Evidence-based Policy and the Medicaid Evidence-based Decisions Project

The Center for Evidence-based Policy (Center) is recognized as a national leader in evidence-based decision making and policy design. The Center understands the needs of policymakers and supports public organizations by providing reliable information to guide decisions, maximize existing resources, improve health outcomes, and reduce unnecessary costs. The Center specializes in ensuring diverse and relevant perspectives are considered, and appropriate resources are leveraged to strategically address complex policy issues with high-quality evidence and collaboration. The Center is based at Oregon Health & Science University in Portland, Oregon.

The Medicaid Evidence-based Decisions Project (MED) is housed at the Center. Its mission is to create an effective collaboration among Medicaid programs and their state partners for the purpose of making high-quality evidence analysis available to support benefit design and coverage decisions made by state programs. Further information about the MED Project and the Center is available at [www.ohsu.edu/policycenter](http://www.ohsu.edu/policycenter).

**Suggested citation: Carson, S., Harrod, C., & King, V. (2016). *Weight-based dosing strategies for factor replacement therapy in hemophilia A and B*. Portland, OR: Center for Evidence-based Policy, Oregon Health & Science University.**

Conflict of Interest Disclosures: No authors have conflicts of interest to disclose. All authors have completed and submitted the Oregon Health & Science University form for Disclosure of Potential Conflicts of Interest, and none were reported.

Funding/Support: This research was funded by the Center for Evidence-based Policy's Medicaid Evidence-based Decisions project at Oregon Health & Science University.

This document was prepared by the Center for Evidence-based Policy at Oregon Health & Science University (Center). This document is intended to support Medicaid Evidence-based Decisions Project (MED) participant organizations and their constituent decision-making bodies to make informed decisions about the provision of health care services. The document is intended as a reference and is provided with the understanding that the Center is not engaged in rendering any clinical, legal, business, or other professional advice. The statements in this document do not represent official policy positions of the Center, the MED Project, or MED participating organizations. Researchers and authors involved in preparing this document have no affiliations or financial involvement that conflict with material presented in this document.